Worldwide Clinical Trials Picked to Manage Phase 3 Study of NurOwn for ALS

Worldwide Clinical Trials Picked to Manage Phase 3 Study of NurOwn for ALS

Worldwide Clinical Trials was selected as the Clinical Research Organization (CRO) to run a Phase 3 study of the investigational stem-cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm Cell Therapeutics, which developed NurOwn, expects the collaboration will provide all of the necessary requirements to pursue the placebo-controlled,…

Military Veterans Twice as Likely to Develop ALS

Military veterans are twice as likely to develop amyotrophic lateral sclerosis (ALS) as those who haven’t served in the military. MORE: Explaining the progression of ALS Despite extensive research into the topic, scientists are still unable to find the link between serving in the military and developing ALS.  According to the…

Mice with ALS-like Disease Function Better and Live Longer When Protein Receptor’s Activity Is Reduced

Researchers have slowed the progression of an ALS-like disease in mice, and prolonged their lives, by reducing the activity of a protein receptor that helps transmit signals between nerve cells. The study, which involved the metabotropic glutamate receptor 5, or mGluR5, was published in the journal Neuropharmacology. The article was titled “…